Abstract

Cognitive disturbances are often reported as serious incapacitating symptoms by patients suffering from major depressive disorders (MDDs). Such deficits have been observed in various animal models based on environmental stress. Here, we performed a complete characterization of cognitive functions in a neuroendocrine mouse model of depression based on a chronic (4 weeks) corticosterone administration (CORT). Cognitive performances were assessed using behavioral tests measuring episodic (novel object recognition test, NORT), associative (one-trial contextual fear conditioning, CFC), and visuo-spatial (Morris water maze, MWM; Barnes maze, BM) learning/memory. Altered emotional phenotype after chronic corticosterone treatment was confirmed in mice using tests predictive of anxiety or depression-related behaviors. In the NORT, CORT-treated mice showed a decrease in time exploring the novel object during the test session and a lower discrimination index compared to control mice, characteristic of recognition memory impairment. Associative memory was also impaired, as observed with a decrease in freezing duration in CORT-treated mice in the CFC, thus pointing out the cognitive alterations in this model. In the MWM and in the BM, spatial learning performance but also short-term spatial memory were altered in CORT-treated mice. In the MWM, unlike control animals, CORT-treated animals failed to learn a new location during the reversal phase, suggesting a loss of cognitive flexibility. Finally, in the BM, the lack of preference for the target quadrant during the recall probe trial in animals receiving corticosterone regimen demonstrates that long-term retention was also affected in this paradigm. Taken together, our results highlight that CORT-induced anxio-depressive-like phenotype is associated with a cognitive deficit affecting all aspects of memory tested.

Highlights

  • The prevalence of depression, a severe psychiatric disease, is constantly high worldwide to the extent that World Health Organization (WHO) estimates that Major Depressive Disorder (MDD) will be the second largest cause of disability in year 2020 (WHO, 2008)

  • Since cognitive symptoms are common among patients with MDD (Fava et al, 2006; Hammar and Ardal, 2009; Murrough et al, 2011; Lee et al, 2012; Millan et al, 2012), investigators have examined the nature of difficulties in cognitive functioning that are associated with depression such as attention (Landro et al, 2001; Ravnkilde et al, 2002; Porter et al, 2003; Lampe et al, 2004), processing speed (Ravnkilde et al, 2002; Hammar et al, 2003; Lampe et al, 2004), executive function (Naismith et al, 2003; Lampe et al, 2004) and learning and memory (Landro et al, 2001; Fossati et al, 2002; Ravnkilde et al, 2002; Porter et al, 2003; Vythilingam et al, 2004)

  • corticosterone administration (CORT)-treated mice developed an anxiety-like phenotype in the Open Field test, characterized by a decrease in time spent in the center compared to control mice (p < 0.05, Figure S1C), but no modification of total ambulatory distance (p > 0.1, Figure S1D)

Read more

Summary

Introduction

The prevalence of depression, a severe psychiatric disease, is constantly high worldwide to the extent that World Health Organization (WHO) estimates that Major Depressive Disorder (MDD) will be the second largest cause of disability in year 2020 (WHO, 2008). A recent literature review e assessed abnormalities in neural circuits and cognition early in the course of MDD Cognitive deficits in memory and decision-making are detected early in the course of MDD and may be associated with structural abnormalities in the hippocampus or cortex (Trivedi and Greer, 2014). New antidepressant drug strategies that target cognitive symptoms are needed to improve long-term outcomes, functional recovery

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call